X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA PANACEA BIOTECH ELDER PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x -0.2 115.6 - View Chart
P/BV x 0.1 2.6 3.9% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ELDER PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
PANACEA BIOTECH
Mar-14
ELDER PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs380149 255.5%   
Low Rs18882 228.4%   
Sales per share (Unadj.) Rs491.284.1 583.8%  
Earnings per share (Unadj.) Rs-3.2-18.3 17.4%  
Cash flow per share (Unadj.) Rs14.4-6.7 -215.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs376.583.7 449.8%  
Shares outstanding (eoy) m20.5461.25 33.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.61.4 42.1%   
Avg P/E ratio x-89.3-6.3 1,414.8%  
P/CF ratio (eoy) x19.7-17.2 -114.3%  
Price / Book Value ratio x0.81.4 54.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m5,8337,074 82.5%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m2,1791,449 150.4%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m10,0895,154 195.8%  
Other income Rs m257100 257.1%   
Total revenues Rs m10,3465,254 196.9%   
Gross profit Rs m-792-766 103.3%  
Depreciation Rs m361711 50.8%   
Interest Rs m2,7561,503 183.4%   
Profit before tax Rs m-3,653-2,881 126.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m3,7131,771 209.7%   
Tax Rs m12517 744.9%   
Profit after tax Rs m-65-1,121 5.8%  
Gross profit margin %-7.8-14.9 52.8%  
Effective tax rate %-3.4-0.6 587.4%   
Net profit margin %-0.6-21.8 3.0%  
BALANCE SHEET DATA
Current assets Rs m9,2403,810 242.5%   
Current liabilities Rs m9,9988,365 119.5%   
Net working cap to sales %-7.5-88.4 8.5%  
Current ratio x0.90.5 202.9%  
Inventory Days Days46156 29.7%  
Debtors Days Days6067 89.2%  
Net fixed assets Rs m10,12414,480 69.9%   
Share capital Rs m20661 335.6%   
"Free" reserves Rs m5,582903 618.1%   
Net worth Rs m7,7345,127 150.8%   
Long term debt Rs m4,8895,832 83.8%   
Total assets Rs m22,88219,433 117.7%  
Interest coverage x-0.3-0.9 35.5%   
Debt to equity ratio x0.61.1 55.6%  
Sales to assets ratio x0.40.3 166.3%   
Return on assets %11.82.0 598.7%  
Return on equity %-0.8-21.9 3.9%  
Return on capital %22.33.6 613.5%  
Exports to sales %3.024.5 12.4%   
Imports to sales %0.410.2 4.2%   
Exports (fob) Rs m3071,264 24.3%   
Imports (cif) Rs m43525 8.2%   
Fx inflow Rs m3071,539 19.9%   
Fx outflow Rs m125942 13.3%   
Net fx Rs m181597 30.4%   
CASH FLOW
From Operations Rs m11,754599 1,961.6%  
From Investments Rs m-561-438 128.0%  
From Financial Activity Rs m-6,762-303 2,234.6%  
Net Cashflow Rs m4,432-141 -3,136.4%  

Share Holding

Indian Promoters % 39.6 74.5 53.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 0.6 1,250.0%  
FIIs % 16.8 1.3 1,292.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 23.6 153.0%  
Shareholders   16,479 10,259 160.6%  
Pledged promoter(s) holding % 77.6 35.1 221.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   DR. DATSONS LABS  DISHMAN PHARMA  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare ELDER PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend; Realty Stocks Top Losers(01:30 pm)

After opening the day lower, share markets in India have continued the downtrend and are currently trading below the dotted line. Sectoral indices are trading on a negative note with stocks.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Gold Imports Surge: Are People Hedging the Risk of Another Demonetisation?(Vivek Kaul's Diary)

Sep 19, 2017

Imports of the yellow metal have surged big time this year.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

A Little-Known Japanese Secret for Compounding Wealth

Sep 22, 2017

What Warren Buffett and Benjamin Graham have in common with a little known Japanese secret.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS